Product Description
For Chronic Obstructive Pulmonary Disease (COPD). a new bronchodilator indicated for treatment of chronic obstructive pulmonary disease (COPD). (Sourced from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002974-20/BE; https://pubmed.ncbi.nlm.nih.gov/16030078/)
Mechanisms of Action: LAM Antagonist,mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Cyprus | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Jordan | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Philippines | Poland | Romania | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Finland
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TESSA | P1 |
Completed |
Healthy Volunteers |
2021-10-04 |
28% |